lysine clonixinate | 55837-30-4

• 物质功能分类: 生物化工 - 常见氨基酸及蛋白质类
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: lysine clonixinate
• 英文别名: clonixin lysinate；(5-amino-5-carboxypentyl)azanium;2-(3-chloro-2-methylanilino)pyridine-3-carboxylate
• CAS: 55837-30-4
• 化学式: C₆H₁₄N₂O₂*C₁₃H₁₁ClN₂O₂
• 分子量: 408.885
• InChiKey: CVNFYQCHAWFYQI-UHFFFAOYSA-N

物化性质

• 熔点：
  208-214°C (dec.)
• 溶解度：
  甲醇（微溶）、水（微溶）

计算性质

• 辛醇/水分配系数(LogP)：
  3.01
• 重原子数：
  28
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  152
• 氢给体数：
  5
• 氢受体数：
  8

制备方法与用途

赖氨酸氯尼辛是一种类白色结晶性粉末，常用于作为非甾体抗炎镇痛药物。

文献信息

• METHODS AND COMPOSITIONS FOR TREATING INFECTION
  申请人：UNIVERSITY OF ROCHESTER

  公开号：US20150238473A1

  公开（公告）日：2015-08-27

  Provided herein are compositions and methods for treating or preventing infection.

  本文提供了用于治疗或预防感染的组合物和方法。
• MANUFACTURING METHOD AND APPARATUS OF ULTRAFINE PARTICLES HAVING UNIFORM PARTICLE SIZE DISTRIBUTION
  申请人：Hwang Sung Joo

  公开号：US20110200678A1

  公开（公告）日：2011-08-18

  The present invention relates to a novel technology for forming fine particles with a size of 0.02˜3 microns from a solid that can be dissolved in a liquid solvent and is not decomposed by heat. The particle preparation technology according to the present invention may be applicable to the fields of food, cosmetics, biopolymer, polymer compositions, and pharmaceuticals.

  本发明涉及一种新型技术，用于从可溶于液体溶剂且不会被热分解的固体中形成粒径为0.02〜3微米的细小颗粒。本发明的颗粒制备技术可适用于食品、化妆品、生物聚合物、聚合物组合物和制药等领域。
• COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND/OR TREATMENT OF DYSBIOSIS AND ANTIBACTERIAL ANTIDOTES FOR MICROBIOME-PROTECTION
  申请人：European Molecular Biology Laboratory

  公开号：EP3838269A1

  公开（公告）日：2021-06-23

  The present invention relates to the field of therapeutics and, more in particular, to pharmaceutical compositions for the prevention and/or treatment of bacterial infections and antibacterial-induced dysfunctions. The invention is based on the identification of compounds that prevent antibacterial effects of antibiotics on microbiome-bacterial species, while retaining antibacterial effects of antibiotics on pathogenic bacteria. The invention also pertains to pharmaceutical compositions comprising antibiotics and antibiotic antidotes for the protection of commensal microbiome-bacteria. Thus, this invention relates to compounds and pharmaceutical combinations useful to prevent antibiotic-induced adverse effects on the gut microbiome. Furthermore provided are methods for preventing an adverse effect on a gut microbiome using the compounds and/or pharmaceutical compositions of this invention.

  本发明涉及治疗学领域，更具体地说，涉及预防和/或治疗细菌感染和抗菌引起的功能障碍的药物组合物。本发明基于对化合物的鉴定，这些化合物可防止抗生素对微生物菌种的抗菌作用，同时保留抗生素对致病菌的抗菌作用。本发明还涉及包含抗生素和抗生素解毒剂的药物组合物，用于保护共生微生物-细菌。因此，本发明涉及有助于防止抗生素对肠道微生物组产生不良影响的化合物和药物组合。此外，本发明还提供了使用本发明化合物和/或药物组合物预防对肠道微生物组的不良影响的方法。
• Methods and compositions for treating infection
  申请人：UNIVERSITY OF ROCHESTER

  公开号：US10004701B2

  公开（公告）日：2018-06-26

  Provided herein are compositions and methods for treating or preventing infection.

  本文提供了用于治疗或预防感染的组合物和方法。
• Apparatus and methods for drug delivery using multiple reservoirs
  申请人：Clearside Biomedical, Inc.

  公开号：US10188550B2

  公开（公告）日：2019-01-29

  A cartridge, including a first member that defines an inner volume and a second member disposed therein, is disposed in a housing. A first reservoir is disposed in the inner volume in a position distal to the second member. The first member is partially disposed in a second reservoir, defined by the housing. The second member is configured to be moved from a first position, in which the first reservoir contains a drug and the second reservoir is fluidically isolated from the inner volume, toward a second position, in which the first reservoir and the second reservoir are in fluid communication with the inner volume, such that the second reservoir receives a volume of the drug from the first reservoir. The first member and the second member are collectively moved relative to the second reservoir to expel the volume of the drug from the second reservoir.

  一个滤芯，包括一个限定内容积的第一部件和一个放置在其中的第二部件，被放置在一个外壳中。第一储液器位于第二部件远端位置的内腔中。第一构件部分设置在由外壳限定的第二储液器中。第二构件被配置为可从第一位置向第二位置移动，在第一位置，第一贮液器含有药物，第二贮液器与内腔流体隔离，在第二位置，第一贮液器和第二贮液器与内腔流体相通，从而第二贮液器从第一贮液器接收一定量的药物。第一构件和第二构件共同相对于第二贮液器移动，以将药物从第二贮液器中排出。